Donate to Kiss Cancer Goodbye — Stand Up To Cancer
Honor Someone you love! Support Stand Up To Cancer this Valentine’s Day and #KissCancerGoodbye
Honor Someone you love! Support Stand Up To Cancer this Valentine’s Day and #KissCancerGoodbye
IASLC presents a one-hour, live session focused on key highlights from the 2024 Hot Topic in Basic & Translational Science Conference. This webinar will…
SSO sponsors educational videoconferences for CGSO Fellows, Residents, and faculty. This session will discuss the management of melanoma in both the localized and metastatic setting.…
PHILADELPHIA (January 31, 2025) — Lilian J. Shin-Cho, PhD, an Assistant Professor in the Cancer Prevention and Control Research Program at Fox Chase Cancer Center,…
It’s difficult to imagine starting a cancer treatment path for a patient without first reviewing their molecular test results. This means getting the comprehensive story…
On February 11, 2025, the Food and Drug Administration approved mirdametinib (Gomekli, SpringWorks Therapeutics, Inc.), a kinase inhibitor, for adult and pediatric patients 2 years…
A full day of programming is dedicated to the tailored treatments that are required to care for this uniquely vulnerable patient population, explains Michael Verneris,…
Northwestern Medicine investigators have developed a new avenue to reprogram compromised immune cells to work against tumors, according to a study published in Science Advances.
Blood Podcast | Blood | American Society of Hematology Blood Podcast The editors of Blood are pleased to introduce a podcast series, published weekly…
Durable remissions were shown in patients with high-risk, relapsed or refractory, IDH1-mutant AML treated with combination of olutasidenib plus azacitidine in multiple studies.